Duration of Response as Clinical Endpoint: A Quick Guide for Clinical Researchers

被引：0
|
作者：
Kim, Seonok [1 ]
Kim, Min-Ju [1 ]
Choe, Jooae [2 ]
机构：
[1] Asan Med Ctr, Dept Clin Epidemiol & Biostat, 88 Olymp Ro 43 Gil, Seoul 05505, South Korea
[2] Univ Ulsan, Asan Med Ctr, Coll Med, Res Inst Radiol,Dept Radiol, Seoul, South Korea
来源：
KOREAN JOURNAL OF RADIOLOGY | 2024年 / 25卷 / 11期
关键词：
Survival analysis; Time-to-event analysis; Statistical method; Duration of response; Probability of being in response;
D O I：
10.3348/kjr.2024.0589
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
引用
收藏
页码：937 / 941
页数：5
相关论文
共 50 条
  • [41] Latent variable indirect response joint modeling of a continuous and a categorical clinical endpoint
    Chuanpu Hu
    Philippe O. Szapary
    Alan M. Mendelsohn
    Honghui Zhou
    Journal of Pharmacokinetics and Pharmacodynamics, 2014, 41 : 335 - 349
  • [42] Clinical response as an endpoint in studies of estrogen replacement therapy in postmenopausal women.
    Simon, JA
    Heuer, M
    FERTILITY AND STERILITY, 2002, 78 (03) : S162 - S162
  • [43] Clinical potential of microdystrophin as a surrogate endpoint
    Boehler, Jessica F.
    Brown, Kristy J.
    Beatka, Margaret
    Gonzalez, J. Patrick
    Dreghici, Roxana Donisa
    Soustek-Kramer, Meghan
    McGonigle, Sharon
    Ganot, Annie
    Palmer, Timothy
    Lowie, Caitlin
    Chamberlain, Jeffrey S.
    Lawlor, Michael W.
    Morris, Carl A.
    NEUROMUSCULAR DISORDERS, 2023, 33 (01) : 40 - 49
  • [44] Mortality in schizophrenia: a measurable clinical endpoint
    Bushe, Chris J.
    Taylor, Mark
    Haukka, Jari
    JOURNAL OF PSYCHOPHARMACOLOGY, 2010, 24 (11) : 17 - 25
  • [45] Endpoint adjudication in cardiovascular clinical trials
    Khan, Muhammad Shahzeb
    Usman, Muhammad Shariq
    Van Spall, Harriette G. C.
    Greene, Stephen J.
    Baqal, Omar
    Felker, Gary Michael
    Bhatt, Deepak L.
    Januzzi, James L.
    Butler, Javed
    EUROPEAN HEART JOURNAL, 2023, 44 (46) : 4835 - 4846
  • [46] Suicidal thinking as a valuable clinical endpoint
    Kleiman, Evan M.
    ECLINICALMEDICINE, 2020, 23
  • [47] The challenges of conducting clinical endpoint studies
    Jonathan L. Isaacsohn
    Tiffany A. Khodadad
    Catherine Soldano-Noble
    Jeffrey D. Vest
    Current Atherosclerosis Reports, 2003, 5 (1) : 11 - 14
  • [48] QUALITY OF LIFE AS AN ENDPOINT OF CLINICAL TRIALS
    Reck, M.
    LUNG CANCER, 2009, 64 : S22 - S23
  • [49] Clinical benefit as a primary efficacy endpoint
    Ballatori, E
    Del Favero, A
    Roila, F
    JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (02) : 803 - 804
  • [50] The role of biomarkers in clinical endpoint success
    Coney, G.
    DRUGS OF THE FUTURE, 2018, 43 (11) : 835 - 837
12345